eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2022
vol. 26
 
Share:
Send email
Share:
abstract:
Original paper

RON, ROR1 and SUSD2 expression in tissues of endometrial carcinoma patients. Clinicopathological and prognostic implications

Abeer M. Abdelbary
1
,
Randa Mohamed Kaf
1
,
Mohamed Elbakry Lashin
2
,
Ahmed Z. Alattar
3
,
Dalia Hamouda Elsayed
3
,
Ahmed F. Amin
4
,
Loay M. Gertallah
5
,
Ahmed Mohamed Yehia
6

  1. Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  2. Gynecology and Obstetrics Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  3. Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  4. Medical OncologyDepartment, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  5. Anesthesia and Intensive care Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  6. General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Contemp Oncol (Pozn) 2022; 26 (2): 109–122
DOI: https://doi.org/10.5114/wo.2022.118245
Online publish date: 2022/06/30
View full text Get citation
 
PlumX metrics:
Introduction
Endometrial carcinoma is now considered a common female gynecologic cancer with increasing incidence, with 13–25% of patients being still liable to recurrence and metastasis, which needs further studies to detect novel targets and new therapies. The aim of the study was evaluate tissue expression of RON, ROR1 and SUSD2 in endometrial carcinoma and atypical endometrial hyperplasia using immunohistochemistry and correlate their expression with clinical, pathological and prognostic parameters of patients.

Material and methods
We included samples from 100 patients with endometrial carcinoma. Sections from paraffin blocks were stained with RON, ROR1 and SUSD2 using immunohistochemistry. Correlations between marker expression, clinicopathological features and prognostic samples were evaluated.

Results
Upregulation of RON and ROR1 and downregulation of SUSD2 expression were found in endometrial carcinoma more than atypical endometrial hyperplasia (p < 0.001). High RON and ROR1 expression levels were significantly associated with high grade (p < 0.001), presence of lymph node metastases (p = 0.003), distant metastases (p = 0.009), advanced International Federation of Gynecology and Obstetrics stage (p = 0.002), poor response to therapy (p = 0.046), and lower recurrence-free survival (RFS) rate (p = 0.002), progression-free survival (PFS) rate (p = 0.008), distant metastasis-free survival (DMFS) rate (p = 0.019) and overall survival rate (p < 0.001). Low SUSD2 expression was significantly associated with older patient age (p = 0.002), large tumor size (p = 0.003), high grade (p = 0.005), presence of adnexal invasion (p = 0.023), presence of lympho-vascular invasion (p = 0.021), extent of myometrial invasion (p = 0.002), lower RFS rate (p = 0.008), lower PFS rate (p = 0.023), and lower DMFS rate (p < 0.001).

Conclusions
Upregulation of RON and ROR1 and downregulation of SUSD2 lead to promotion of endometrial cancer cell proliferation, migration, epithelial-mesenchymal transition, and invasion.

keywords:

endometrial carcinoma, RON, ROR1 and SUSD2, prognosis
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.